CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

China's Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million deal

By Reuters News

Nov 5 - Qyuns Therapeutics 2509.HK is licensing an early-stage antibody program to US biotech Caldera Therapeutics in a deal worth up to $750 million plus an upfront fee, the Hong Kong-listed firm said on Thursday.


Here are some details:

  • Caldera gets exclusive worldwide rights to develop, manufacture, seek approval for and sell drug candidates from the program, while Qyuns will receive $30 million upfront, plus up to $750 million tied to development, regulatory and commercial milestones

  • The Jiangsu-headquartered company will also get tiered royalties on net sales for a set period after a product first goes on sale

  • The program covers antibodies designed to block two immune-related targets, TL1A and IL-17

  • The deal adds to Qyuns' growing track record of out-licensing, following a milestone payment it received from Roche ROPC.S in May after the first participant was dosed in a Phase 1 trial of a separate drug


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.